Soligenix Expands European Medical Advisory Board to Advance Cutaneous T-Cell Lymphoma Treatment
Soligenix Inc. has expanded its European Medical Advisory Board to guide the confirmatory Phase 3 trial of HyBryte for early-stage cutaneous T-cell lymphoma, strengthening European engagement ahead of potential commercialization of this novel photodynamic therapy.
Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte in early-stage cutaneous T-cell lymphoma. The 18-week study is enrolling approximately 80 patients with top-line results expected in the second half of 2026, as the company strengthens European engagement ahead of potential commercialization.
The expansion of the European Medical Advisory Board represents a strategic move to ensure regional expertise guides the clinical development of HyBryte, which represents a novel approach to treating this rare form of cancer. Cutaneous T-cell lymphoma is a rare disease with limited treatment options, particularly for early-stage patients who often face challenging side effects from existing therapies. HyBryte utilizes synthetic hypericin sodium as a photodynamic therapy that employs safe visible light, potentially offering a better tolerated treatment alternative.
This development matters because successful completion of the second Phase 3 study could lead to regulatory approvals supporting commercialization worldwide, addressing a significant unmet medical need in the rare disease space. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, with development programs also including expansion of synthetic hypericin into psoriasis treatment. Additional pipeline candidates include first-in-class innate defense regulator technology dusquetide for inflammatory diseases including oral mucositis in head and neck cancer.
The timing of this European expansion coincides with the company's broader strategic positioning for global market access. By strengthening its European advisory capabilities now, Soligenix demonstrates foresight in preparing for potential regulatory submissions and market entry in key European territories. The company maintains additional development programs in its Public Health Solutions business segment, including vaccine candidates for ricin toxin, filoviruses such as Marburg and Ebola, and CiVax for COVID-19 prevention, though these programs are supported through separate government funding mechanisms.
For investors and stakeholders following the company's progress, the latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. The full press release detailing the European Medical Advisory Board expansion can be viewed at https://ibn.fm/b9dsR. This strategic move underscores Soligenix's commitment to advancing rare disease treatments through targeted regional expertise and global development strategies.